Inari Medical price target lowered to $100 from $105 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Inari Medical to $100 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 sales ahead of expectations and raised its 2023 sales guidance. Improving profitability remains a key focus even as Inari invest behind key growth drivers, Wells adds. The firm believes six new products in FMR in the second half of the year should help maintain momentum.